Prices of Pirfenidone/Acerex plummeted after being included in medical insurance

Pirfenidone/Pirfenidone is a drug used to treat idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is a progressive lung disease characterized by progressive scarring of lung tissue, leading to decreased lung function and difficulty breathing. The exact cause of the disease is still unclear, and it is more common in middle-aged and elderly people. Its incidence has gradually increased in recent years, causing serious impact on patients' quality of life and survival rate.

The mechanism of pirfenidone mainly slows down the fibrosis process of lung tissue through anti-fibrosis and anti-inflammatory effects. Studies have found that pirfenidone can inhibit the synthesis of a variety of biologically active substances, such as transforming growth factor β (TGF-β), which is closely related to the fibrosis process. In addition, pirfenidone also reduces lung tissue damage by reducing oxidative stress and improving cell apoptosis.

In terms of clinical application, pirfenidone is usually administered in oral form, and patients need to gradually increase the dose according to the doctor's advice in order to minimize side effects. Common side effects include gastrointestinal discomfort, fatigue, rash, etc.

In China, the high price of pirfenidone after it was launched on the market has made it difficult for many patients to bear the financial burden of long-term treatment. However, with the adjustment of the national medical insurance policy, pirfenidone was included in the medical insurance catalog, which greatly alleviated the financial pressure on patients. After being included in Medicare, the price of pirfenidone dropped significantly, making this effective treatment affordable for more patients.

The inclusion of pirfenidone in medical insurance not only reduces the cost of medication for patients, but also promotes progress in the treatment of pulmonary fibrosis. More patients can use this drug, providing more data and resources for clinical research and disease treatment, and helping to further explore and optimize treatment options for idiopathic pulmonary fibrosis.